CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Financial Officer acquired 237,358 shares (grant or award)
- 4 Grant or award General Counsel acquired 175,438 shares (grant or award)
- 4 Open-market sale EVP of R&D and CMO sold 5,169 shares at $7.71 ($39,848)
- 4 Open-market sale General Counsel sold 8,849 shares at $7.68 ($67,962)
- 4 Open-market sale President and CEO sold 23,648 shares at $7.65 ($180,879)
- 4 Open-market sale Chief Financial Officer sold 11,469 shares at $7.63 ($87,551)
- 4 Open-market sale Chief Technical Officer sold 8,698 shares at $7.63 ($66,388)
- 4 Gift Director gave 412,618 shares (gift)
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 3 Insider Initial Statement of Ownership
- SC 13D/A Stake Beneficial Ownership Report
Page 18 of 30 · 587 filings